Last reviewed · How we verify
Decrease per-dialytic heparin therapy
At a glance
| Generic name | Decrease per-dialytic heparin therapy |
|---|---|
| Sponsor | CHU de Reims |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparison of HYDROLINK™ and HeprAN™ mEmbranes in a Per Dialytic Heparin Weaning Strategy in Chronic Hemodialysis Patients (NA)
- Possibility to Stop Perdialytic Heparin Therapy in Hemodialysed Patients With HeprAN ™ Membrane and Treated by Long-term Anticoagulation With VKA (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Decrease per-dialytic heparin therapy CI brief — competitive landscape report
- Decrease per-dialytic heparin therapy updates RSS · CI watch RSS
- CHU de Reims portfolio CI